Oss, Netherlands

Meertinus Jan Smit

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: N.v. Organon. Active years: 2012.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Meertinus Jan Smit: Innovator in Polypeptide Conjugates

Introduction

Meertinus Jan Smit is a notable inventor based in Oss, Netherlands. He has made significant contributions to the field of biochemistry, particularly in the development of conjugates that enhance the pharmacokinetic properties of polypeptides.

Latest Patents

Smit holds a patent for "Conjugates of a polypeptide and a pentasaccharide." This invention relates to conjugates of a polypeptide and an oligosaccharide. The polypeptide is conjugated to at least one oligosaccharide-spacer residue. The oligosaccharide is a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and has an affinity to antithrombin III. The spacer is a bond or an essentially pharmacologically inactive flexible linking residue, or a pharmaceutically acceptable salt thereof. The conjugates of this invention exhibit improved pharmacokinetic properties compared to the original polypeptides.

Career Highlights

Meertinus Jan Smit is associated with N.V. Organon, a company known for its focus on pharmaceutical innovations. His work has contributed to advancements in drug development and therapeutic applications.

Collaborations

Smit has collaborated with notable colleagues, including Ebo S Bos and Martin De Kort. These collaborations have fostered a productive environment for innovation and research.

Conclusion

Meertinus Jan Smit's contributions to the field of polypeptide conjugates highlight his role as an influential inventor. His work continues to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…